Prognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinoma Treated With Vascular Endothelial Growth Factor-Targeting Agents

被引:24
作者
Cetin, Bulent [1 ]
Kaplan, Mehmet Ali [2 ]
Berk, Veli [3 ]
Ozturk, Selcuk Cemil [2 ]
Benekli, Mustafa [1 ]
Isikdogan, Abdurrahman [2 ]
Ozkan, Metin [3 ]
Coskun, Ugur [1 ]
Buyukberber, Suleyman [1 ]
机构
[1] Gazi Univ, Dept Internal Med, Fac Med, Ankara, Turkey
[2] Dicle Univ, Dept Internal Med, Fac Med, Diyarbakir, Turkey
[3] Erciyes Univ, Dept Internal Med, Fac Med, Div Med Oncol, Kayseri, Turkey
关键词
Vascular endothelial growth factor; bevacizumab; prognostic factors; metastatic colorectal cancer; PROGRESSION-FREE SURVIVAL; SURROGATE END-POINTS; RENAL-CELL CARCINOMA; BREAST-CANCER; METRONOMIC CHEMOTHERAPY; DEHYDROGENASE LEVEL; PREDICT SURVIVAL; THROMBOCYTOSIS; FLUOROURACIL; OXALIPLATIN;
D O I
10.7314/APJCP.2012.13.3.1059
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Angiogenesis represents a key element in the pathogenesis of malignancy. There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer treated with vascular endothelial growth factor (VEGF)-targeted therapy. The present study was conducted to establish a prognostic model for patients using an oxaliplatin-based or irinotecan-based chemotherapy plus bevacizumab in metastatic colorectal cancer. Methods: Baseline characteristics and outcomes on 170 patients treated with FOLFIRI or XELOX plus anti-VEGF therapy-naive metastatic colorectal cancer were collected from three Turkey cancer centers. Cox proportional hazards regression was used to identify independent prognostic factors for OS. Results: The median OS for the whole cohort was 19 months (95% CI, 14.3 to 23.6 months). Three of the seven adverse prognostic factors according to the Anatolian Society of Medical Oncology (ASMO) were independent predictors of short survival: serum lactate dehydrogenase (LDH) greater than the upper limit of normal (ULN; p<0.001); neutrophils greater than the ULN (p<0.0014); and progression free survival (PFS) less than 6 months (p=0.001). Conclusion: Serum LDH and neutrophil levels were the main prognostic factors in predicting survival, followed by PFS. This model validates incorporation of components of the ASMO model into patient care and clinical trials that use VEGF-targeting agents.
引用
收藏
页码:1059 / 1063
页数:5
相关论文
共 24 条
[1]   Validation of surrogate end points in multiple randomized clinical trials with failure time end points [J].
Burzykowski, T ;
Molenberghs, G .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2001, 50 :405-422
[2]   Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer [J].
Burzykowski, Tomasz ;
Buyse, Marc ;
Piccart-Gebhart, Martine J. ;
Sledge, George ;
Carmichael, James ;
Lueck, Hans-Joachim ;
Mackey, John R. ;
Nabholtz, Jean-Marc ;
Paridaens, Robert ;
Biganzoli, Laura ;
Jassem, Jacek ;
Bontenbal, Marijke ;
Bonneterre, Jacques ;
Chan, Stephen ;
Basaran, Gul Atalay ;
Therasse, Patrick .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :1987-1992
[3]   Progression-free survival is a surrogate for survival in advanced colorectal cancer [J].
Buyse, Marc ;
Burzykowski, Tomasz ;
Carroll, Kevin ;
Michiels, Stefan ;
Sargent, Daniel J. ;
Miller, Langdon L. ;
Elfring, Gary L. ;
Pignon, Jean-Pierre ;
Piedbois, Pascal .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5218-5224
[4]   PROGNOSTIC FACTORS IN AGGRESSIVE MALIGNANT-LYMPHOMAS - DESCRIPTION AND VALIDATION OF A PROGNOSTIC INDEX THAT COULD IDENTIFY PATIENTS REQUIRING A MORE INTENSIVE THERAPY [J].
COIFFIER, B ;
GISSELBRECHT, C ;
VOSE, JM ;
TILLY, H ;
HERBRECHT, R ;
BOSLY, A ;
ARMITAGE, JO .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (02) :211-219
[5]   Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer?: Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals [J].
Collette, L ;
Burzykowski, T ;
Carroll, KJ ;
Newling, D ;
Morris, T ;
Schröder, FH .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6139-6148
[6]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[7]   HIGH SERUM LACTATE-DEHYDROGENASE LEVEL AS A MARKER FOR DRUG-RESISTANCE AND SHORT SURVIVAL IN MULTIPLE-MYELOMA [J].
DIMOPOULOS, MA ;
BARLOGIE, B ;
SMITH, TL ;
ALEXANIAN, R .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (12) :931-935
[8]   Impact of immune parameters on long-term survival in metastatic renal cell carcinoma [J].
Donskov, F ;
von der Maase, H .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :1997-2005
[9]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400
[10]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611